MR Imaging Accurately Determines Prostate Cancer Treatment Failure
May 24th, 2008 Posted in hifuA new study shows that dynamic contrast-enhanced MRI (DCE-MRI) plus diffusion weighted imaging (DWI) can accurately diagnose residual or recurrent prostate cancer in patients treated with high-intensity focused ultrasonic (HIFU) ablation. The study found that DWI had fewer false positives than DCE-MRI, but DCE-MRI had fewer false negatives.
The lead author of the study said that DCE-MRI and DWI had about a 72% accuracy rate in determining which patients needed additional treatment because they had residual or recurrent cancer.
HIFU is becoming more common as a prostate cancer treatment option, particularly for those persons who can’t or don’t want to undergo a radical prostatectomy.
The study appears in the May issue of the American Journal of Roentgenology, published by the American Roentgen Ray Society.